SIMILAR PATTERNS OF AMINO ACIDS FOR 3LZS_A_017A200_1

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1b4e	PROTEIN (5-AMINOLEVULINIC ACID DEHYDRATASE) (Escherichia coli)	PF00490 (ALAD)	5	GLY A 305 ALA A 306 ASP A 307 ILE A 255 ILE A 301	None	0.87A	3lzsA-1b4eA: undetectable	3lzsA-1b4eA: 13.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1e69	CHROMOSOME SEGREGATION SMC PROTEIN (Thermotoga maritima)	PF02463 (SMC_N)	5	LEU A1092 GLY A1085 ALA A1087 GLY A1043 VAL A1026	None	0.95A	3lzsA-1e69A: undetectable	3lzsA-1e69A: 18.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1hvc	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	A79 A 800 ( 4.0A) A79 A 800 (-2.8A) A79 A 800 (-3.0A) A79 A 800 (-3.2A) A79 A 800 (-2.7A) A79 A 800 ( 4.7A) A79 A 800 ( 4.3A) A79 A 800 (-3.4A) A79 A 800 ( 4.0A) A79 A 800 ( 3.4A) A79 A 800 (-4.5A) A79 A 800 (-3.8A)	0.38A	3lzsA-1hvcA: 13.7	3lzsA-1hvcA: 45.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1hvc	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	11	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 ILE A 50 VAL A 82 ILE A 84	A79 A 800 ( 3.8A) A79 A 800 (-2.7A) A79 A 800 (-3.0A) A79 A 800 (-3.1A) A79 A 800 (-2.8A) A79 A 800 ( 4.9A) A79 A 800 ( 4.4A) A79 A 800 ( 3.7A) A79 A 800 (-3.8A) A79 A 800 (-4.5A) A79 A 800 (-3.6A)	0.43A	3lzsA-1hvcA: 13.7	3lzsA-1hvcA: 45.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1hvc	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 PRO A 81 VAL A 82 ILE A 84	A79 A 800 ( 3.8A) A79 A 800 (-2.7A) A79 A 800 (-3.0A) A79 A 800 (-3.1A) A79 A 800 ( 4.9A) A79 A 800 ( 4.4A) A79 A 800 ( 3.9A) A79 A 800 (-4.5A) A79 A 800 (-3.6A)	0.53A	3lzsA-1hvcA: 13.7	3lzsA-1hvcA: 45.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1kae	HISTIDINOL DEHYDROGENASE (Escherichia coli)	PF00815 (Histidinol_dh)	5	GLY A 227 ALA A 228 ASP A 204 GLY A 196 ILE A 206	None	0.84A	3lzsA-1kaeA: undetectable	3lzsA-1kaeA: 13.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1q9p	HIV-1 PROTEASE (Homo sapiens)	PF00077 (RVP)	7	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 84	None	0.51A	3lzsA-1q9pA: 9.9	3lzsA-1q9pA: 88.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1qho	ALPHA-AMYLASE (Geobacillus stearothermophilus)	PF00128 (Alpha-amylase) PF00686 (CBM_20) PF01833 (TIG) PF02806 (Alpha-amylase_C)	5	LEU A 71 GLY A 53 ASP A 21 VAL A 74 ILE A 16	None None CA A 698 (-3.2A) None None	0.97A	3lzsA-1qhoA: undetectable	3lzsA-1qhoA: 9.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1siv	SIV PROTEASE (Simian immunodeficiency virus)	PF00077 (RVP)	10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.41A	3lzsA-1sivA: 19.0	3lzsA-1sivA: 51.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1tcs	TRICHOSANTHIN (Trichosanthes kirilowii)	PF00161 (RIP)	5	LEU A 215 GLY A 231 ALA A 230 VAL A 213 ILE A 225	None	0.94A	3lzsA-1tcsA: undetectable	3lzsA-1tcsA: 15.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1to3	PUTATIVE ALDOLASE YIHT (Salmonella enterica)	PF01791 (DeoC)	5	LEU A 184 GLY A 188 ALA A 189 ASP A 190 ILE A 158	None	0.78A	3lzsA-1to3A: undetectable	3lzsA-1to3A: 18.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1u2e	2-HYDROXY-6-KETONONA -2,4-DIENEDIOIC ACID HYDROLASE (Escherichia coli)	PF12697 (Abhydrolase_6)	5	LEU A 281 GLY A 61 ALA A 60 ILE A 54 VAL A 277	None	0.85A	3lzsA-1u2eA: undetectable	3lzsA-1u2eA: 20.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1usy	ATP PHOSPHORIBOSYLTRANSF ERASE REGULATORY SUBUNIT (Thermotoga maritima)	PF13393 (tRNA-synt_His)	5	ALA C 251 VAL C 114 ILE C 238 VAL C 109 ILE C 113	None	0.65A	3lzsA-1usyC: undetectable	3lzsA-1usyC: 16.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1v5f	PYRUVATE OXIDASE (Aerococcus viridans)	PF00205 (TPP_enzyme_M) PF02775 (TPP_enzyme_C) PF02776 (TPP_enzyme_N)	5	ASP A 388 ALA A 444 ASP A 442 VAL A 466 ILE A 440	None TPP A1602 (-3.7A) MG A1603 ( 2.8A) None None	0.89A	3lzsA-1v5fA: undetectable	3lzsA-1v5fA: 11.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1v5j	KIAA1355 PROTEIN (Homo sapiens)	PF00041 (fn3)	5	GLY A 85 ALA A 84 VAL A 33 GLY A 60 PRO A 11	None	0.98A	3lzsA-1v5jA: undetectable	3lzsA-1v5jA: 21.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1wsv	AMINOMETHYLTRANSFERA SE (Homo sapiens)	PF01571 (GCV_T) PF08669 (GCV_T_C)	5	LEU A 152 VAL A 192 GLY A 166 VAL A 207 ILE A 205	LEU A 152 ( 0.6A) VAL A 192 ( 0.6A) GLY A 166 ( 0.0A) VAL A 207 ( 0.6A) ILE A 205 ( 0.4A)	0.85A	3lzsA-1wsvA: undetectable	3lzsA-1wsvA: 14.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2bc0	NADH OXIDASE (Streptococcus pyogenes)	PF02852 (Pyr_redox_dim) PF07992 (Pyr_redox_2)	5	GLY A 453 ALA A 454 ASP A 456 ILE A 387 ILE A 426	None	0.61A	3lzsA-2bc0A: undetectable	3lzsA-2bc0A: 12.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2cvj	THIOREDOXIN REDUCTASE RELATED PROTEIN (Thermus thermophilus)	PF00890 (FAD_binding_2) PF07992 (Pyr_redox_2)	5	LEU A 170 GLY A 24 ALA A 23 ASP A 177 VAL A 164	None	0.93A	3lzsA-2cvjA: undetectable	3lzsA-2cvjA: 20.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2fmb	EQUINE INFECTIOUS ANEMIA VIRUS PROTEASE (Equine infectious anemia virus)	PF00077 (RVP)	5	ASP A 25 ALA A 28 VAL A 32 GLY A 54 ILE A 89	LP1 A 201 (-2.3A) LP1 A 201 (-3.5A) None LP1 A 201 (-3.6A) LP1 A 201 (-4.2A)	0.76A	3lzsA-2fmbA: 15.2	3lzsA-2fmbA: 34.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2fmb	EQUINE INFECTIOUS ANEMIA VIRUS PROTEASE (Equine infectious anemia virus)	PF00077 (RVP)	10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 55 PRO A 86 VAL A 87 ILE A 89	None LP1 A 201 (-2.3A) LP1 A 201 (-3.8A) LP1 A 201 (-3.5A) LP1 A 201 (-3.6A) None LP1 A 201 (-3.4A) LP1 A 201 (-3.9A) LP1 A 201 ( 4.9A) LP1 A 201 (-4.2A)	0.47A	3lzsA-2fmbA: 15.2	3lzsA-2fmbA: 34.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2g28	PYRUVATE DEHYDROGENASE E1 COMPONENT (Escherichia coli)	PF00456 (Transketolase_N)	5	LEU A 565 GLY A 573 PRO A 594 VAL A 516 ILE A 518	None	0.81A	3lzsA-2g28A: undetectable	3lzsA-2g28A: 8.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2gzl	2-C-METHYL-D-ERYTHRI TOL 2,4-CYCLODIPHOSPHATE SYNTHASE (Escherichia coli)	PF02542 (YgbB)	5	GLY A 37 ASP A 8 GLY A 145 PRO A 103 ILE A 20	None ZN A 900 ( 2.4A) None None None	0.94A	3lzsA-2gzlA: undetectable	3lzsA-2gzlA: 24.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2h00	METHYLTRANSFERASE 10 DOMAIN CONTAINING PROTEIN (Homo sapiens)	PF05971 (Methyltransf_10)	5	GLY A 84 ALA A 85 GLY A 69 VAL A 120 ILE A 118	None None None DTU A2140 (-4.0A) None	0.95A	3lzsA-2h00A: undetectable	3lzsA-2h00A: 18.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2p4z	METAL-DEPENDENT HYDROLASES OF THE BETA-LACTAMASE SUPERFAMILY II (Caldanaerobacter subterraneus)	PF00753 (Lactamase_B)	5	LEU A 38 GLY A 145 ILE A 149 VAL A 47 ILE A 45	None	0.89A	3lzsA-2p4zA: undetectable	3lzsA-2p4zA: 15.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ph3	3-OXOACYL-[ACYL CARRIER PROTEIN] REDUCTASE (Thermus thermophilus)	PF13561 (adh_short_C2)	5	LEU A 28 GLY A 14 ALA A 9 VAL A 56 ILE A 30	None	0.94A	3lzsA-2ph3A: undetectable	3lzsA-2ph3A: 19.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ri6	2-HYDROXY-6-OXO-6-PH ENYLHEXA-2,4-DIENOAT E HYDROLASE (Paraburkholderia xenovorans)	PF12697 (Abhydrolase_6)	5	LEU A 283 GLY A 63 ALA A 62 VAL A 279 ILE A 280	None	0.82A	3lzsA-2ri6A: undetectable	3lzsA-2ri6A: 14.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2rkf	PROTEASE RETROPEPSIN (Human immunodeficiency virus 1)	PF00077 (RVP)	10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None AB1 A 501 (-2.4A) AB1 A 501 (-3.9A) AB1 A 501 (-3.5A) AB1 A 501 ( 3.3A) AB1 A 501 (-3.8A) AB1 A 501 (-3.5A) AB1 A 501 (-3.8A) AB1 A 501 (-4.2A) AB1 A 501 ( 4.2A)	0.32A	3lzsA-2rkfA: 20.9	3lzsA-2rkfA: 81.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2rsp	RSV PROTEASE (Rous sarcoma virus)	PF00077 (RVP)	6	LEU A 35 ASP A 37 GLY A 39 ALA A 40 ASP A 41 ILE A 108	None	0.40A	3lzsA-2rspA: 12.9	3lzsA-2rspA: 33.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2wsk	GLYCOGEN DEBRANCHING ENZYME (Escherichia coli)	PF00128 (Alpha-amylase) PF02922 (CBM_48)	5	LEU A 188 GLY A 255 ALA A 254 ILE A 248 ILE A 185	None	0.73A	3lzsA-2wskA: undetectable	3lzsA-2wskA: 9.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ww9	SEC SIXTY-ONE PROTEIN HOMOLOG (Saccharomyces cerevisiae)	PF00344 (SecY) PF10559 (Plug_translocon)	5	GLY A 40 ALA A 39 VAL A 170 ILE A 33 ILE A 171	None	0.93A	3lzsA-2ww9A: undetectable	3lzsA-2ww9A: 12.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3aqp	PROBABLE SECDF PROTEIN-EXPORT MEMBRANE PROTEIN (Thermus thermophilus)	PF02355 (SecD_SecF) PF07549 (Sec_GG)	5	GLY A 327 ALA A 329 GLY A 274 ILE A 271 VAL A 693	None	0.92A	3lzsA-3aqpA: undetectable	3lzsA-3aqpA: 9.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3b8b	CYSQ, SULFITE SYNTHESIS PATHWAY PROTEIN (Bacteroides thetaiotaomicron)	PF00459 (Inositol_P)	6	ALA A 6 ASP A 5 VAL A 112 GLY A 11 ILE A 14 ILE A 100	None	1.27A	3lzsA-3b8bA: undetectable	3lzsA-3b8bA: 16.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3c26	PUTATIVE ACETYLTRANSFERASE TA0821 (Thermoplasma acidophilum)	PF00583 (Acetyltransf_1)	5	ASP A 45 GLY A 87 ILE A 74 VAL A 56 ILE A 52	NO3 A 266 (-3.1A) EDO A 269 (-3.4A) None None None	0.94A	3lzsA-3c26A: undetectable	3lzsA-3c26A: 20.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3c26	PUTATIVE ACETYLTRANSFERASE TA0821 (Thermoplasma acidophilum)	PF00583 (Acetyltransf_1)	5	ASP A 45 VAL A 51 GLY A 87 ILE A 74 VAL A 56	NO3 A 266 (-3.1A) None EDO A 269 (-3.4A) None None	0.97A	3lzsA-3c26A: undetectable	3lzsA-3c26A: 20.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3c4n	UNCHARACTERIZED PROTEIN DR_0571 (Deinococcus radiodurans)	PF01266 (DAO)	5	LEU A 370 GLY A 200 VAL A 40 VAL A 230 ILE A 228	None	0.87A	3lzsA-3c4nA: undetectable	3lzsA-3c4nA: 11.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3dbg	PUTATIVE CYTOCHROME P450 (Streptomyces coelicolor)	PF00067 (p450)	5	GLY A 359 ALA A 360 ASP A 361 PRO A 24 ILE A 356	None	0.84A	3lzsA-3dbgA: undetectable	3lzsA-3dbgA: 10.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3hdy	UDP-GALACTOPYRANOSE MUTASE (Deinococcus radiodurans)	PF03275 (GLF) PF13450 (NAD_binding_8)	5	GLY A 38 ALA A 37 VAL A 237 VAL A 55 ILE A 57	FAD A 450 (-3.3A) None None None None	0.88A	3lzsA-3hdyA: undetectable	3lzsA-3hdyA: 14.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3hh1	TETRAPYRROLE METHYLASE FAMILY PROTEIN (Chlorobaculum tepidum)	PF00590 (TP_methylase)	5	LEU A 79 GLY A 111 ALA A 110 VAL A 75 ILE A 76	None	0.87A	3lzsA-3hh1A: undetectable	3lzsA-3hh1A: 22.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3jv7	ADH-A (Rhodococcus ruber)	PF00107 (ADH_zinc_N) PF08240 (ADH_N)	5	LEU A 211 GLY A 216 ALA A 217 ASP A 218 ILE A 190	None	0.68A	3lzsA-3jv7A: undetectable	3lzsA-3jv7A: 13.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3khz	PUTATIVE DIPEPTIDASE SACOL1801 (Staphylococcus aureus)	PF01546 (Peptidase_M20)	5	LEU A 130 GLY A 73 ALA A 72 GLY A 80 ILE A 127	None	0.82A	3lzsA-3khzA: undetectable	3lzsA-3khzA: 10.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3kyh	MRNA-CAPPING ENZYME SUBUNIT BETA (Saccharomyces cerevisiae)	PF02940 (mRNA_triPase)	5	ALA A 337 ASP A 336 ASP A 315 VAL A 322 ILE A 313	None	0.95A	3lzsA-3kyhA: undetectable	3lzsA-3kyhA: 15.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3lad	DIHYDROLIPOAMIDE DEHYDROGENASE (Azotobacter vinelandii)	PF02852 (Pyr_redox_dim) PF07992 (Pyr_redox_2)	5	LEU A 239 GLY A 187 ALA A 188 GLY A 196 ILE A 238	None	0.88A	3lzsA-3ladA: undetectable	3lzsA-3ladA: 12.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3lun	ULILYSIN (Methanosarcina acetivorans)	PF05572 (Peptidase_M43)	5	ALA A 209 ASP A 207 VAL A 175 ILE A 93 ILE A 205	None	0.90A	3lzsA-3lunA: undetectable	3lzsA-3lunA: 15.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mq0	TRANSCRIPTIONAL REPRESSOR OF THE BLCABC OPERON (Agrobacterium tumefaciens)	PF01614 (IclR) PF09339 (HTH_IclR)	5	LEU A 240 GLY A 254 VAL A 121 PRO A 118 ILE A 238	None	0.93A	3lzsA-3mq0A: undetectable	3lzsA-3mq0A: 15.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 PRO A 81 VAL A 82 ILE A 84	None	0.45A	3lzsA-3mwsA: 20.1	3lzsA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	11	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.29A	3lzsA-3mwsA: 20.1	3lzsA-3mwsA: 79.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3njx	RHAMNOGALACTURONASE B (Aspergillus aculeatus)	PF09284 (RhgB_N) PF14683 (CBM-like) PF14686 (fn3_3)	5	GLY A 346 ASP A 349 VAL A 336 GLY A 420 ILE A 419	None CA A 800 (-2.9A) None None None	0.97A	3lzsA-3njxA: undetectable	3lzsA-3njxA: 11.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3o8l	6-PHOSPHOFRUCTOKINAS E, MUSCLE TYPE (Oryctolagus cuniculus)	PF00365 (PFK)	5	GLY A 224 ALA A 225 ASP A 226 VAL A 207 ILE A 261	PO4 A 767 ( 4.6A) None None None None	0.95A	3lzsA-3o8lA: undetectable	3lzsA-3o8lA: 9.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3s8m	ENOYL-ACP REDUCTASE (Xanthomonas oryzae)	PF07055 (Eno-Rase_FAD_bd) PF12241 (Enoyl_reductase) PF12242 (Eno-Rase_NADH_b)	5	GLY A 213 ALA A 212 ILE A 206 VAL A 121 ILE A 122	None	0.82A	3lzsA-3s8mA: undetectable	3lzsA-3s8mA: 14.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3slz	GAG-PRO-POL POLYPROTEIN (Murine leukemia virus)	PF00077 (RVP)	5	ASP A 32 GLY A 34 ALA A 35 VAL A 39 PRO A 89	3TL A 126 (-2.4A) 3TL A 126 (-3.1A) 3TL A 126 ( 4.0A) None 3TL A 126 (-4.0A)	0.56A	3lzsA-3slzA: 11.3	3lzsA-3slzA: 25.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3slz	GAG-PRO-POL POLYPROTEIN (Murine leukemia virus)	PF00077 (RVP)	6	LEU A 30 ASP A 32 GLY A 34 ALA A 35 VAL A 39 GLY A 56	None 3TL A 126 (-2.4A) 3TL A 126 (-3.1A) 3TL A 126 ( 4.0A) None 3TL A 126 (-3.4A)	0.50A	3lzsA-3slzA: 11.3	3lzsA-3slzA: 25.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3t3c	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	6	LEU A 23 ASP A 25 ALA A 28 ASP A 30 GLY A 49 ILE A 50	SO4 A 101 (-4.2A) 017 A 201 (-2.6A) 017 A 201 (-3.5A) 017 A 201 (-4.2A) 017 A 201 (-4.0A) 017 A 201 (-3.3A)	1.25A	3lzsA-3t3cA: 19.4	3lzsA-3t3cA: 80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3t3c	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81	SO4 A 101 (-4.2A) 017 A 201 (-2.6A) 017 A 201 (-3.4A) 017 A 201 (-3.5A) 017 A 201 (-3.5A) 017 A 201 (-4.2A) None 017 A 201 (-4.0A) 017 A 201 (-3.3A) None	0.60A	3lzsA-3t3cA: 19.4	3lzsA-3t3cA: 80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ttp	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None 017 A 201 (-2.6A) 017 A 201 (-3.6A) 017 A 201 (-3.4A) 017 A 201 (-3.3A) 017 A 201 (-4.6A) 017 A 201 (-3.0A) 017 A 201 (-3.3A) 017 A 201 (-4.1A) 017 A 201 (-4.7A)	0.31A	3lzsA-3ttpA: 20.3	3lzsA-3ttpA: 82.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3u7s	POL POLYPROTEIN (Human immunodeficiency virus 1)	PF00077 (RVP)	6	LEU A 23 ASP A 25 ALA A 28 ASP A 30 GLY A 49 ILE A 50	None 017 A 202 ( 2.5A) 017 A 201 (-3.4A) 017 A 201 ( 4.0A) 017 A 202 (-2.9A) 017 A 201 ( 3.5A)	1.26A	3lzsA-3u7sA: 19.8	3lzsA-3u7sA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3u7s	POL POLYPROTEIN (Human immunodeficiency virus 1)	PF00077 (RVP)	9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 50 PRO A 81	None 017 A 202 ( 2.5A) 017 A 201 ( 3.5A) 017 A 201 (-3.4A) 017 A 201 (-3.2A) 017 A 201 ( 4.0A) 017 A 202 (-2.9A) 017 A 201 ( 3.5A) 017 A 202 (-4.0A)	0.36A	3lzsA-3u7sA: 19.8	3lzsA-3u7sA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3uhl	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	7	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 PRO A 81 VAL A 82	None	0.42A	3lzsA-3uhlA: 16.4	3lzsA-3uhlA: 80.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4clc	UPF0303 PROTEIN YBR137W (Saccharomyces cerevisiae)	PF03928 (Haem_degrading)	5	LEU E 151 ALA E 160 GLY E 43 VAL E 59 ILE E 148	None	0.95A	3lzsA-4clcE: undetectable	3lzsA-4clcE: 18.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4g09	HISTIDINOL DEHYDROGENASE (Brucella suis)	PF00815 (Histidinol_dh)	6	LEU A 240 ALA A 243 ASP A 244 GLY A 352 ILE A 351 ILE A 241	None	1.35A	3lzsA-4g09A: undetectable	3lzsA-4g09A: 12.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	PF00001 (7tm_1)	5	VAL A 44 GLY A 90 ILE A 94 VAL A 39 ILE A 43	None	0.87A	3lzsA-4gbrA: undetectable	3lzsA-4gbrA: 12.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4inj	LMO1638 PROTEIN (Listeria monocytogenes)	PF02016 (Peptidase_S66)	5	LEU A 162 ALA A 309 GLY A 306 ILE A 305 ILE A 321	None	0.84A	3lzsA-4injA: undetectable	3lzsA-4injA: 16.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4kpo	NUCLEOSIDE N-RIBOHYDROLASE 3 (Zea mays)	PF01156 (IU_nuc_hydro)	5	GLY A 10 ASP A 12 GLY A 124 ILE A 34 ILE A 17	None CA A 401 ( 4.8A) CA A 401 ( 4.3A) None None	0.89A	3lzsA-4kpoA: undetectable	3lzsA-4kpoA: 17.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4lom	IMIDAZOLEGLYCEROL-PH OSPHATE DEHYDRATASE (Mycobacterium tuberculosis)	PF00475 (IGPD)	5	LEU A 165 GLY A 84 ALA A 161 VAL A 116 ILE A 163	None	0.85A	3lzsA-4lomA: undetectable	3lzsA-4lomA: 19.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4m2j	AMINOTRANSFERASE (Streptomyces lavendulae)	PF00155 (Aminotran_1_2)	5	GLY A 278 ALA A 281 VAL A 311 GLY A 228 ILE A 200	None	0.93A	3lzsA-4m2jA: undetectable	3lzsA-4m2jA: 14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4maa	PUTATIVE BRANCHED-CHAIN AMINO ACID ABC TRANSPORTER, PERIPLASMIC AMINO ACID-BINDING PROTEIN (Pseudomonas protegens)	PF13458 (Peripla_BP_6)	5	LEU A 105 GLY A 128 ALA A 129 ASP A 130 GLY A 179	GOL A 503 ( 4.4A) GOL A 503 (-3.7A) None None None	0.90A	3lzsA-4maaA: undetectable	3lzsA-4maaA: 13.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4na3	POLYKETIDE SYNTHASE PKSJ (Bacillus subtilis)	PF00109 (ketoacyl-synt) PF02801 (Ketoacyl-synt_C) PF16197 (KAsynt_C_assoc)	5	LEU A 180 GLY A 201 ALA A 200 ILE A 12 ILE A 183	None	0.97A	3lzsA-4na3A: undetectable	3lzsA-4na3A: 9.92
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4njv	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	5	ALA A 28 ASP A 29 ASP A 30 GLY A 48 ILE A 84	RIT A 500 (-3.6A) RIT A 500 (-3.2A) RIT A 500 (-4.8A) RIT A 500 (-4.8A) RIT A 500 (-4.3A)	0.73A	3lzsA-4njvA: 20.1	3lzsA-4njvA: 82.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4njv	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 PRO A 81 ILE A 84	None RIT A 500 (-2.4A) RIT A 500 (-3.9A) RIT A 500 (-3.6A) RIT A 500 (-3.2A) RIT A 500 (-4.8A) None RIT A 500 (-3.9A) RIT A 500 (-4.3A)	0.49A	3lzsA-4njvA: 20.1	3lzsA-4njvA: 82.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4njv	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None RIT A 500 (-2.4A) RIT A 500 (-3.9A) RIT A 500 (-3.6A) RIT A 500 (-3.2A) None RIT A 500 (-3.4A) RIT A 500 (-4.3A) RIT A 500 (-3.9A) RIT A 500 (-4.3A)	0.39A	3lzsA-4njvA: 20.1	3lzsA-4njvA: 82.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4qlz	SJCHGC07024 PROTEIN (Schistosoma japonicum)	PF00719 (Pyrophosphatase)	5	LEU A 17 GLY A 20 PRO A 31 VAL A 30 ILE A 24	None	0.74A	3lzsA-4qlzA: undetectable	3lzsA-4qlzA: 15.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4r1u	CINNAMOYL COA REDUCTASE (Medicago truncatula)	PF01370 (Epimerase)	5	GLY A 97 ASP A 59 GLY A 8 VAL A 70 ILE A 66	None	0.87A	3lzsA-4r1uA: undetectable	3lzsA-4r1uA: 14.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4rwe	SUGAR-BINDING TRANSPORT PROTEIN (Yersinia pestis)	PF13407 (Peripla_BP_4)	5	GLY A 196 ALA A 190 ILE A 223 VAL A 214 ILE A 156	None None GOL A 401 ( 4.2A) None None	0.90A	3lzsA-4rweA: undetectable	3lzsA-4rweA: 18.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4rzk	SMALL HEAT SHOCK PROTEIN HSP20 FAMILY (Sulfolobus solfataricus)	PF00011 (HSP20)	5	LEU A 121 ALA A 87 ILE A 90 PRO A 139 ILE A 136	None	0.92A	3lzsA-4rzkA: undetectable	3lzsA-4rzkA: 25.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4tnb	G PROTEIN-COUPLED RECEPTOR KINASE 5 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	5	LEU A 45 ASP A 52 GLY A 63 ILE A 62 ILE A 49	None	0.90A	3lzsA-4tnbA: undetectable	3lzsA-4tnbA: 10.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ydf	HTLV-1 PROTEASE (Primate T-lymphotropic virus 1)	PF00077 (RVP)	7	ASP A 32 GLY A 34 ALA A 35 ASP A 36 VAL A 39 GLY A 58 ILE A 100	4B1 A 201 (-2.9A) 4B1 A 201 ( 4.6A) 4B1 A 201 (-3.6A) 4B1 A 201 (-4.4A) None 4B1 A 201 (-3.4A) 4B1 A 201 (-4.8A)	0.53A	3lzsA-4ydfA: 13.1	3lzsA-4ydfA: 32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ydf	HTLV-1 PROTEASE (Primate T-lymphotropic virus 1)	PF00077 (RVP)	7	LEU A 30 ASP A 32 GLY A 34 ALA A 35 ASP A 36 GLY A 58 ILE A 100	None 4B1 A 201 (-2.9A) 4B1 A 201 ( 4.6A) 4B1 A 201 (-3.6A) 4B1 A 201 (-4.4A) 4B1 A 201 (-3.4A) 4B1 A 201 (-4.8A)	0.43A	3lzsA-4ydfA: 13.1	3lzsA-4ydfA: 32.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4z26	PUTATIVE GMC-TYPE OXIDOREDUCTASE R135 (Acanthamoeba polyphaga mimivirus)	PF00732 (GMC_oxred_N) PF05199 (GMC_oxred_C)	5	LEU A 36 VAL A 296 ILE A 267 VAL A 10 ILE A 12	None	0.79A	3lzsA-4z26A: undetectable	3lzsA-4z26A: 9.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ztk	CELL DIVISION PROTEIN FTSI/PENICILLIN BINDING PROTEIN 2 (Legionella pneumophila)	PF00905 (Transpeptidase)	5	LEU A 512 ALA A 367 GLY A 364 ILE A 600 ILE A 509	None	0.97A	3lzsA-4ztkA: undetectable	3lzsA-4ztkA: 16.61
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5b18	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	6	GLY A 27 ALA A 28 ASP A 29 ASP A 30 PRO A 81 ILE A 84	None	0.40A	3lzsA-5b18A: 17.7	3lzsA-5b18A: 72.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5b18	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	5	GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 84	None	0.73A	3lzsA-5b18A: 17.7	3lzsA-5b18A: 72.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5cw5	BRCA1/BRCA2-CONTAINI NG COMPLEX SUBUNIT 3 (Camponotus floridanus)	PF01398 (JAB)	5	LEU A 79 VAL A 89 GLY A 33 ILE A 51 ILE A 36	None	0.96A	3lzsA-5cw5A: undetectable	3lzsA-5cw5A: 14.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5fmg	PROTEASOME, PUTATIVE (Plasmodium falciparum)	PF00227 (Proteasome)	5	ASP H 157 VAL H 12 ILE H 37 VAL H 231 ILE H 233	None	0.95A	3lzsA-5fmgH: undetectable	3lzsA-5fmgH: 14.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5h1k	GEM-ASSOCIATED PROTEIN 5 (Homo sapiens)	PF00400 (WD40) PF12894 (ANAPC4_WD40)	5	LEU A 157 GLY A 132 VAL A 177 VAL A 167 ILE A 169	None	0.76A	3lzsA-5h1kA: undetectable	3lzsA-5h1kA: 9.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5h34	METHIONINE-TRNA LIGASE (Nanoarchaeum equitans)	PF01588 (tRNA_bind)	5	LEU A 713 GLY A 716 VAL A 690 VAL A 704 ILE A 702	None	0.94A	3lzsA-5h34A: undetectable	3lzsA-5h34A: 17.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5h4b	CEREBELLIN-4 (Mus musculus)	PF00386 (C1q)	5	GLY A 143 ALA A 142 VAL A 117 GLY A 173 VAL A 120	None	0.98A	3lzsA-5h4bA: undetectable	3lzsA-5h4bA: 19.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5hs0	ANKYRIN DOMAIN PROTEIN ANK1C4_7 (synthetic construct)	PF12796 (Ank_2)	5	LEU A 121 GLY A 126 ALA A 127 ASP A 128 VAL A 86	None	0.96A	3lzsA-5hs0A: undetectable	3lzsA-5hs0A: 19.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5t2z	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	6	LEU A 23 ASP A 25 ALA A 28 ASP A 30 GLY A 49 PRO A 81	None	1.39A	3lzsA-5t2zA: 21.0	3lzsA-5t2zA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5t2z	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	11	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.26A	3lzsA-5t2zA: 21.0	3lzsA-5t2zA: 77.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5u2w	SHORT CHAIN DEHYDROGENASE (Burkholderia cenocepacia)	PF00106 (adh_short)	5	ALA A 170 ASP A 172 GLY A 164 ILE A 163 VAL A 137	None	0.95A	3lzsA-5u2wA: undetectable	3lzsA-5u2wA: 17.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ve3	BPPRF (Paraburkholderia phytofirmans)	no annotation	5	GLY B 88 ALA B 89 ASP B 90 VAL B 59 ILE B 80	None	0.72A	3lzsA-5ve3B: undetectable	3lzsA-5ve3B: 14.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5vm2	ALCOHOL DEHYDROGENASE (Escherichia coli)	PF00107 (ADH_zinc_N) PF08240 (ADH_N)	5	GLY A 237 ALA A 238 ASP A 239 VAL A 199 ILE A 173	None	0.83A	3lzsA-5vm2A: undetectable	3lzsA-5vm2A: 15.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5xj1	UNCHARACTERIZED RNA METHYLTRANSFERASE SP_1029 (Streptococcus pneumoniae)	no annotation	5	GLY A 399 ALA A 400 ASP A 401 ILE A 373 ILE A 378	None	0.89A	3lzsA-5xj1A: undetectable	3lzsA-5xj1A: 14.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6b92	U6 SMALL NUCLEAR RNA (ADENINE-(43)-N(6))- METHYLTRANSFERASE (Homo sapiens)	no annotation	5	GLY A 121 ALA A 122 GLY A 106 VAL A 157 ILE A 155	None	0.95A	3lzsA-6b92A: undetectable	3lzsA-6b92A: 15.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fiv	RETROPEPSIN (Feline immunodeficiency virus)	PF00077 (RVP)	6	LEU A 28 ASP A 30 GLY A 32 ALA A 33 ASP A 34 GLY A 58	None 3TL A 201 (-3.5A) 3TL A 201 (-3.4A) 3TL A 201 (-4.0A) 3TL A 201 (-3.9A) 3TL A 201 (-3.4A)	0.19A	3lzsA-6fivA: 15.5	3lzsA-6fivA: 29.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fiv	RETROPEPSIN (Feline immunodeficiency virus)	PF00077 (RVP)	6	LEU A 28 ASP A 30 GLY A 32 ALA A 33 ASP A 34 VAL A 99	None 3TL A 201 (-3.5A) 3TL A 201 (-3.4A) 3TL A 201 (-4.0A) 3TL A 201 (-3.9A) None	0.45A	3lzsA-6fivA: 15.5	3lzsA-6fivA: 29.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6upj	HIV-2 PROTEASE (Human immunodeficiency virus 2)	PF00077 (RVP)	8	LEU A 23 ASP A 25 ALA A 28 ASP A 29 ASP A 30 GLY A 49 PRO A 81 ILE A 84	None NIU A 100 (-2.8A) NIU A 100 (-3.6A) None None NIU A 100 ( 3.8A) None None	0.63A	3lzsA-6upjA: 18.2	3lzsA-6upjA: 51.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6upj	HIV-2 PROTEASE (Human immunodeficiency virus 2)	PF00077 (RVP)	8	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 84	None NIU A 100 (-2.8A) NIU A 100 (-4.5A) NIU A 100 (-3.6A) None None NIU A 100 ( 3.8A) None	0.60A	3lzsA-6upjA: 18.2	3lzsA-6upjA: 51.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6upj	HIV-2 PROTEASE (Human immunodeficiency virus 2)	PF00077 (RVP)	7	LEU A 23 ASP A 29 ASP A 30 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None None None NIU A 100 ( 3.8A) NIU A 100 (-3.9A) None None	0.85A	3lzsA-6upjA: 18.2	3lzsA-6upjA: 51.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6upj	HIV-2 PROTEASE (Human immunodeficiency virus 2)	PF00077 (RVP)	6	LEU A 23 ASP A 30 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None None NIU A 100 ( 3.8A) NIU A 100 (-3.9A) None None	1.22A	3lzsA-6upjA: 18.2	3lzsA-6upjA: 51.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6upj	HIV-2 PROTEASE (Human immunodeficiency virus 2)	PF00077 (RVP)	7	LEU A 23 GLY A 27 ASP A 29 ASP A 30 GLY A 49 ILE A 50 ILE A 84	None NIU A 100 (-4.5A) None None NIU A 100 ( 3.8A) NIU A 100 (-3.9A) None	0.78A	3lzsA-6upjA: 18.2	3lzsA-6upjA: 51.52

[["3LZS_A_017A200_1","1b4e","Escherichia coli","PROTEIN (5-AMINOLEVULINIC ACID DEHYDRATASE)","PF00490(ALAD)",5,"GLY A 305;ALA A 306;ASP A 307;ILE A 255;ILE A 301","None","0.87A","3lzsA-1b4eA:undetectable","3lzsA-1b4eA:13.23"],["3LZS_A_017A200_1","1e69","Thermotoga maritima","CHROMOSOME SEGREGATION SMC PROTEIN","PF02463(SMC_N)",5,"LEU A1092;GLY A1085;ALA A1087;GLY A1043;VAL A1026","None","0.95A","3lzsA-1e69A:undetectable","3lzsA-1e69A:18.40"],["3LZS_A_017A200_1","1hvc","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",12,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","A79 A 800 ( 4.0A);A79 A 800 (-2.8A);A79 A 800 (-3.0A);A79 A 800 (-3.2A);A79 A 800 (-2.7A);A79 A 800 ( 4.7A);A79 A 800 ( 4.3A);A79 A 800 (-3.4A);A79 A 800 ( 4.0A);A79 A 800 ( 3.4A);A79 A 800 (-4.5A);A79 A 800 (-3.8A)","0.38A","3lzsA-1hvcA:13.7","3lzsA-1hvcA:45.81"],["3LZS_A_017A200_1","1hvc","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;ILE A  50;VAL A  82;ILE A  84","A79 A 800 ( 3.8A);A79 A 800 (-2.7A);A79 A 800 (-3.0A);A79 A 800 (-3.1A);A79 A 800 (-2.8A);A79 A 800 ( 4.9A);A79 A 800 ( 4.4A);A79 A 800 ( 3.7A);A79 A 800 (-3.8A);A79 A 800 (-4.5A);A79 A 800 (-3.6A)","0.43A","3lzsA-1hvcA:13.7","3lzsA-1hvcA:45.81"],["3LZS_A_017A200_1","1hvc","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;PRO A  81;VAL A  82;ILE A  84","A79 A 800 ( 3.8A);A79 A 800 (-2.7A);A79 A 800 (-3.0A);A79 A 800 (-3.1A);A79 A 800 ( 4.9A);A79 A 800 ( 4.4A);A79 A 800 ( 3.9A);A79 A 800 (-4.5A);A79 A 800 (-3.6A)","0.53A","3lzsA-1hvcA:13.7","3lzsA-1hvcA:45.81"],["3LZS_A_017A200_1","1kae","Escherichia coli","HISTIDINOL DEHYDROGENASE","PF00815(Histidinol_dh)",5,"GLY A 227;ALA A 228;ASP A 204;GLY A 196;ILE A 206","None","0.84A","3lzsA-1kaeA:undetectable","3lzsA-1kaeA:13.23"],["3LZS_A_017A200_1","1q9p","Homo sapiens","HIV-1 PROTEASE","PF00077(RVP)",7,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  84","None","0.51A","3lzsA-1q9pA:9.9","3lzsA-1q9pA:88.42"],["3LZS_A_017A200_1","1qho","Geobacillus stearothermophilus","ALPHA-AMYLASE","PF00128(Alpha-amylase);PF00686(CBM_20);PF01833(TIG);PF02806(Alpha-amylase_C)",5,"LEU A  71;GLY A  53;ASP A  21;VAL A  74;ILE A  16","None;None; CA A 698 (-3.2A);None;None","0.97A","3lzsA-1qhoA:undetectable","3lzsA-1qhoA:9.56"],["3LZS_A_017A200_1","1siv","Simian immunodeficiency virus","SIV PROTEASE","PF00077(RVP)",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.41A","3lzsA-1sivA:19.0","3lzsA-1sivA:51.52"],["3LZS_A_017A200_1","1tcs","Trichosanthes kirilowii","TRICHOSANTHIN","PF00161(RIP)",5,"LEU A 215;GLY A 231;ALA A 230;VAL A 213;ILE A 225","None","0.94A","3lzsA-1tcsA:undetectable","3lzsA-1tcsA:15.98"],["3LZS_A_017A200_1","1to3","Salmonella enterica","PUTATIVE ALDOLASE YIHT","PF01791(DeoC)",5,"LEU A 184;GLY A 188;ALA A 189;ASP A 190;ILE A 158","None","0.78A","3lzsA-1to3A:undetectable","3lzsA-1to3A:18.64"],["3LZS_A_017A200_1","1u2e","Escherichia coli","2-HYDROXY-6-KETONONA-2,4-DIENEDIOIC ACID HYDROLASE","PF12697(Abhydrolase_6)",5,"LEU A 281;GLY A  61;ALA A  60;ILE A  54;VAL A 277","None","0.85A","3lzsA-1u2eA:undetectable","3lzsA-1u2eA:20.36"],["3LZS_A_017A200_1","1usy","Thermotoga maritima","ATP PHOSPHORIBOSYLTRANSFERASE REGULATORY SUBUNIT","PF13393(tRNA-synt_His)",5,"ALA C 251;VAL C 114;ILE C 238;VAL C 109;ILE C 113","None","0.65A","3lzsA-1usyC:undetectable","3lzsA-1usyC:16.47"],["3LZS_A_017A200_1","1v5f","Aerococcus viridans","PYRUVATE OXIDASE","PF00205(TPP_enzyme_M);PF02775(TPP_enzyme_C);PF02776(TPP_enzyme_N)",5,"ASP A 388;ALA A 444;ASP A 442;VAL A 466;ILE A 440","None;TPP A1602 (-3.7A); MG A1603 ( 2.8A);None;None","0.89A","3lzsA-1v5fA:undetectable","3lzsA-1v5fA:11.32"],["3LZS_A_017A200_1","1v5j","Homo sapiens","KIAA1355 PROTEIN","PF00041(fn3)",5,"GLY A  85;ALA A  84;VAL A  33;GLY A  60;PRO A  11","None","0.98A","3lzsA-1v5jA:undetectable","3lzsA-1v5jA:21.74"],["3LZS_A_017A200_1","1wsv","Homo sapiens","AMINOMETHYLTRANSFERASE","PF01571(GCV_T);PF08669(GCV_T_C)",5,"LEU A 152;VAL A 192;GLY A 166;VAL A 207;ILE A 205","LEU A 152 ( 0.6A);VAL A 192 ( 0.6A);GLY A 166 ( 0.0A);VAL A 207 ( 0.6A);ILE A 205 ( 0.4A)","0.85A","3lzsA-1wsvA:undetectable","3lzsA-1wsvA:14.13"],["3LZS_A_017A200_1","2bc0","Streptococcus pyogenes","NADH OXIDASE","PF02852(Pyr_redox_dim);PF07992(Pyr_redox_2)",5,"GLY A 453;ALA A 454;ASP A 456;ILE A 387;ILE A 426","None","0.61A","3lzsA-2bc0A:undetectable","3lzsA-2bc0A:12.87"],["3LZS_A_017A200_1","2cvj","Thermus thermophilus","THIOREDOXIN REDUCTASE RELATED PROTEIN","PF00890(FAD_binding_2);PF07992(Pyr_redox_2)",5,"LEU A 170;GLY A  24;ALA A  23;ASP A 177;VAL A 164","None","0.93A","3lzsA-2cvjA:undetectable","3lzsA-2cvjA:20.93"],["3LZS_A_017A200_1","2fmb","Equine infectious anemia virus","EQUINE INFECTIOUS ANEMIA VIRUS PROTEASE","PF00077(RVP)",5,"ASP A  25;ALA A  28;VAL A  32;GLY A  54;ILE A  89","LP1 A 201 (-2.3A);LP1 A 201 (-3.5A);None;LP1 A 201 (-3.6A);LP1 A 201 (-4.2A)","0.76A","3lzsA-2fmbA:15.2","3lzsA-2fmbA:34.62"],["3LZS_A_017A200_1","2fmb","Equine infectious anemia virus","EQUINE INFECTIOUS ANEMIA VIRUS PROTEASE","PF00077(RVP)",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  55;PRO A  86;VAL A  87;ILE A  89","None;LP1 A 201 (-2.3A);LP1 A 201 (-3.8A);LP1 A 201 (-3.5A);LP1 A 201 (-3.6A);None;LP1 A 201 (-3.4A);LP1 A 201 (-3.9A);LP1 A 201 ( 4.9A);LP1 A 201 (-4.2A)","0.47A","3lzsA-2fmbA:15.2","3lzsA-2fmbA:34.62"],["3LZS_A_017A200_1","2g28","Escherichia coli","PYRUVATE DEHYDROGENASE E1 COMPONENT","PF00456(Transketolase_N)",5,"LEU A 565;GLY A 573;PRO A 594;VAL A 516;ILE A 518","None","0.81A","3lzsA-2g28A:undetectable","3lzsA-2g28A:8.52"],["3LZS_A_017A200_1","2gzl","Escherichia coli","2-C-METHYL-D-ERYTHRITOL 2,4-CYCLODIPHOSPHATE SYNTHASE","PF02542(YgbB)",5,"GLY A  37;ASP A   8;GLY A 145;PRO A 103;ILE A  20","None; ZN A 900 ( 2.4A);None;None;None","0.94A","3lzsA-2gzlA:undetectable","3lzsA-2gzlA:24.62"],["3LZS_A_017A200_1","2h00","Homo sapiens","METHYLTRANSFERASE 10 DOMAIN CONTAINING PROTEIN","PF05971(Methyltransf_10)",5,"GLY A  84;ALA A  85;GLY A  69;VAL A 120;ILE A 118","None;None;None;DTU A2140 (-4.0A);None","0.95A","3lzsA-2h00A:undetectable","3lzsA-2h00A:18.22"],["3LZS_A_017A200_1","2p4z","Caldanaerobacter subterraneus","METAL-DEPENDENT HYDROLASES OF THE BETA-LACTAMASE SUPERFAMILY II","PF00753(Lactamase_B)",5,"LEU A  38;GLY A 145;ILE A 149;VAL A  47;ILE A  45","None","0.89A","3lzsA-2p4zA:undetectable","3lzsA-2p4zA:15.41"],["3LZS_A_017A200_1","2ph3","Thermus thermophilus","3-OXOACYL-[ACYL CARRIER PROTEIN] REDUCTASE","PF13561(adh_short_C2)",5,"LEU A  28;GLY A  14;ALA A   9;VAL A  56;ILE A  30","None","0.94A","3lzsA-2ph3A:undetectable","3lzsA-2ph3A:19.17"],["3LZS_A_017A200_1","2ri6","Paraburkholderia xenovorans","2-HYDROXY-6-OXO-6-PHENYLHEXA-2,4-DIENOATE HYDROLASE","PF12697(Abhydrolase_6)",5,"LEU A 283;GLY A  63;ALA A  62;VAL A 279;ILE A 280","None","0.82A","3lzsA-2ri6A:undetectable","3lzsA-2ri6A:14.79"],["3LZS_A_017A200_1","2rkf","Human immunodeficiency virus 1","PROTEASE RETROPEPSIN","PF00077(RVP)",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None;AB1 A 501 (-2.4A);AB1 A 501 (-3.9A);AB1 A 501 (-3.5A);AB1 A 501 ( 3.3A);AB1 A 501 (-3.8A);AB1 A 501 (-3.5A);AB1 A 501 (-3.8A);AB1 A 501 (-4.2A);AB1 A 501 ( 4.2A)","0.32A","3lzsA-2rkfA:20.9","3lzsA-2rkfA:81.82"],["3LZS_A_017A200_1","2rsp","Rous sarcoma virus","RSV PROTEASE","PF00077(RVP)",6,"LEU A  35;ASP A  37;GLY A  39;ALA A  40;ASP A  41;ILE A 108","None","0.40A","3lzsA-2rspA:12.9","3lzsA-2rspA:33.60"],["3LZS_A_017A200_1","2wsk","Escherichia coli","GLYCOGEN DEBRANCHING ENZYME","PF00128(Alpha-amylase);PF02922(CBM_48)",5,"LEU A 188;GLY A 255;ALA A 254;ILE A 248;ILE A 185","None","0.73A","3lzsA-2wskA:undetectable","3lzsA-2wskA:9.35"],["3LZS_A_017A200_1","2ww9","Saccharomyces cerevisiae","SEC SIXTY-ONE PROTEIN HOMOLOG","PF00344(SecY);PF10559(Plug_translocon)",5,"GLY A  40;ALA A  39;VAL A 170;ILE A  33;ILE A 171","None","0.93A","3lzsA-2ww9A:undetectable","3lzsA-2ww9A:12.22"],["3LZS_A_017A200_1","3aqp","Thermus thermophilus","PROBABLE SECDF PROTEIN-EXPORT MEMBRANE PROTEIN","PF02355(SecD_SecF);PF07549(Sec_GG)",5,"GLY A 327;ALA A 329;GLY A 274;ILE A 271;VAL A 693","None","0.92A","3lzsA-3aqpA:undetectable","3lzsA-3aqpA:9.34"],["3LZS_A_017A200_1","3b8b","Bacteroides thetaiotaomicron","CYSQ, SULFITE SYNTHESIS PATHWAY PROTEIN","PF00459(Inositol_P)",6,"ALA A   6;ASP A   5;VAL A 112;GLY A  11;ILE A  14;ILE A 100","None","1.27A","3lzsA-3b8bA:undetectable","3lzsA-3b8bA:16.20"],["3LZS_A_017A200_1","3c26","Thermoplasma acidophilum","PUTATIVE ACETYLTRANSFERASE TA0821","PF00583(Acetyltransf_1)",5,"ASP A  45;GLY A  87;ILE A  74;VAL A  56;ILE A  52","NO3 A 266 (-3.1A);EDO A 269 (-3.4A);None;None;None","0.94A","3lzsA-3c26A:undetectable","3lzsA-3c26A:20.83"],["3LZS_A_017A200_1","3c26","Thermoplasma acidophilum","PUTATIVE ACETYLTRANSFERASE TA0821","PF00583(Acetyltransf_1)",5,"ASP A  45;VAL A  51;GLY A  87;ILE A  74;VAL A  56","NO3 A 266 (-3.1A);None;EDO A 269 (-3.4A);None;None","0.97A","3lzsA-3c26A:undetectable","3lzsA-3c26A:20.83"],["3LZS_A_017A200_1","3c4n","Deinococcus radiodurans","UNCHARACTERIZED PROTEIN DR_0571","PF01266(DAO)",5,"LEU A 370;GLY A 200;VAL A  40;VAL A 230;ILE A 228","None","0.87A","3lzsA-3c4nA:undetectable","3lzsA-3c4nA:11.70"],["3LZS_A_017A200_1","3dbg","Streptomyces coelicolor","PUTATIVE CYTOCHROME P450","PF00067(p450)",5,"GLY A 359;ALA A 360;ASP A 361;PRO A  24;ILE A 356","None","0.84A","3lzsA-3dbgA:undetectable","3lzsA-3dbgA:10.06"],["3LZS_A_017A200_1","3hdy","Deinococcus radiodurans","UDP-GALACTOPYRANOSE MUTASE","PF03275(GLF);PF13450(NAD_binding_8)",5,"GLY A  38;ALA A  37;VAL A 237;VAL A  55;ILE A  57","FAD A 450 (-3.3A);None;None;None;None","0.88A","3lzsA-3hdyA:undetectable","3lzsA-3hdyA:14.03"],["3LZS_A_017A200_1","3hh1","Chlorobaculum tepidum","TETRAPYRROLE METHYLASE FAMILY PROTEIN","PF00590(TP_methylase)",5,"LEU A  79;GLY A 111;ALA A 110;VAL A  75;ILE A  76","None","0.87A","3lzsA-3hh1A:undetectable","3lzsA-3hh1A:22.40"],["3LZS_A_017A200_1","3jv7","Rhodococcus ruber","ADH-A","PF00107(ADH_zinc_N);PF08240(ADH_N)",5,"LEU A 211;GLY A 216;ALA A 217;ASP A 218;ILE A 190","None","0.68A","3lzsA-3jv7A:undetectable","3lzsA-3jv7A:13.91"],["3LZS_A_017A200_1","3khz","Staphylococcus aureus","PUTATIVE DIPEPTIDASE SACOL1801","PF01546(Peptidase_M20)",5,"LEU A 130;GLY A  73;ALA A  72;GLY A  80;ILE A 127","None","0.82A","3lzsA-3khzA:undetectable","3lzsA-3khzA:10.02"],["3LZS_A_017A200_1","3kyh","Saccharomyces cerevisiae","MRNA-CAPPING ENZYME SUBUNIT BETA","PF02940(mRNA_triPase)",5,"ALA A 337;ASP A 336;ASP A 315;VAL A 322;ILE A 313","None","0.95A","3lzsA-3kyhA:undetectable","3lzsA-3kyhA:15.70"],["3LZS_A_017A200_1","3lad","Azotobacter vinelandii","DIHYDROLIPOAMIDE DEHYDROGENASE","PF02852(Pyr_redox_dim);PF07992(Pyr_redox_2)",5,"LEU A 239;GLY A 187;ALA A 188;GLY A 196;ILE A 238","None","0.88A","3lzsA-3ladA:undetectable","3lzsA-3ladA:12.45"],["3LZS_A_017A200_1","3lun","Methanosarcina acetivorans","ULILYSIN","PF05572(Peptidase_M43)",5,"ALA A 209;ASP A 207;VAL A 175;ILE A  93;ILE A 205","None","0.90A","3lzsA-3lunA:undetectable","3lzsA-3lunA:15.81"],["3LZS_A_017A200_1","3mq0","Agrobacterium tumefaciens","TRANSCRIPTIONAL REPRESSOR OF THE BLCABC OPERON","PF01614(IclR);PF09339(HTH_IclR)",5,"LEU A 240;GLY A 254;VAL A 121;PRO A 118;ILE A 238","None","0.93A","3lzsA-3mq0A:undetectable","3lzsA-3mq0A:15.85"],["3LZS_A_017A200_1","3mws","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;PRO A  81;VAL A  82;ILE A  84","None","0.45A","3lzsA-3mwsA:20.1","3lzsA-3mwsA:79.80"],["3LZS_A_017A200_1","3mws","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.29A","3lzsA-3mwsA:20.1","3lzsA-3mwsA:79.80"],["3LZS_A_017A200_1","3njx","Aspergillus aculeatus","RHAMNOGALACTURONASE B","PF09284(RhgB_N);PF14683(CBM-like);PF14686(fn3_3)",5,"GLY A 346;ASP A 349;VAL A 336;GLY A 420;ILE A 419","None; CA A 800 (-2.9A);None;None;None","0.97A","3lzsA-3njxA:undetectable","3lzsA-3njxA:11.62"],["3LZS_A_017A200_1","3o8l","Oryctolagus cuniculus","6-PHOSPHOFRUCTOKINASE, MUSCLE TYPE","PF00365(PFK)",5,"GLY A 224;ALA A 225;ASP A 226;VAL A 207;ILE A 261","PO4 A 767 ( 4.6A);None;None;None;None","0.95A","3lzsA-3o8lA:undetectable","3lzsA-3o8lA:9.12"],["3LZS_A_017A200_1","3s8m","Xanthomonas oryzae","ENOYL-ACP REDUCTASE","PF07055(Eno-Rase_FAD_bd);PF12241(Enoyl_reductase);PF12242(Eno-Rase_NADH_b)",5,"GLY A 213;ALA A 212;ILE A 206;VAL A 121;ILE A 122","None","0.82A","3lzsA-3s8mA:undetectable","3lzsA-3s8mA:14.75"],["3LZS_A_017A200_1","3slz","Murine leukemia virus","GAG-PRO-POL POLYPROTEIN","PF00077(RVP)",5,"ASP A  32;GLY A  34;ALA A  35;VAL A  39;PRO A  89","3TL A 126 (-2.4A);3TL A 126 (-3.1A);3TL A 126 ( 4.0A);None;3TL A 126 (-4.0A)","0.56A","3lzsA-3slzA:11.3","3lzsA-3slzA:25.19"],["3LZS_A_017A200_1","3slz","Murine leukemia virus","GAG-PRO-POL POLYPROTEIN","PF00077(RVP)",6,"LEU A  30;ASP A  32;GLY A  34;ALA A  35;VAL A  39;GLY A  56","None;3TL A 126 (-2.4A);3TL A 126 (-3.1A);3TL A 126 ( 4.0A);None;3TL A 126 (-3.4A)","0.50A","3lzsA-3slzA:11.3","3lzsA-3slzA:25.19"],["3LZS_A_017A200_1","3t3c","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;GLY A  49;ILE A  50","SO4 A 101 (-4.2A);017 A 201 (-2.6A);017 A 201 (-3.5A);017 A 201 (-4.2A);017 A 201 (-4.0A);017 A 201 (-3.3A)","1.25A","3lzsA-3t3cA:19.4","3lzsA-3t3cA:80.81"],["3LZS_A_017A200_1","3t3c","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81","SO4 A 101 (-4.2A);017 A 201 (-2.6A);017 A 201 (-3.4A);017 A 201 (-3.5A);017 A 201 (-3.5A);017 A 201 (-4.2A);None;017 A 201 (-4.0A);017 A 201 (-3.3A);None","0.60A","3lzsA-3t3cA:19.4","3lzsA-3t3cA:80.81"],["3LZS_A_017A200_1","3ttp","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None;017 A 201 (-2.6A);017 A 201 (-3.6A);017 A 201 (-3.4A);017 A 201 (-3.3A);017 A 201 (-4.6A);017 A 201 (-3.0A);017 A 201 (-3.3A);017 A 201 (-4.1A);017 A 201 (-4.7A)","0.31A","3lzsA-3ttpA:20.3","3lzsA-3ttpA:82.83"],["3LZS_A_017A200_1","3u7s","Human immunodeficiency virus 1","POL POLYPROTEIN","PF00077(RVP)",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;GLY A  49;ILE A  50","None;017 A 202 ( 2.5A);017 A 201 (-3.4A);017 A 201 ( 4.0A);017 A 202 (-2.9A);017 A 201 ( 3.5A)","1.26A","3lzsA-3u7sA:19.8","3lzsA-3u7sA:76.77"],["3LZS_A_017A200_1","3u7s","Human immunodeficiency virus 1","POL POLYPROTEIN","PF00077(RVP)",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  50;PRO A  81","None;017 A 202 ( 2.5A);017 A 201 ( 3.5A);017 A 201 (-3.4A);017 A 201 (-3.2A);017 A 201 ( 4.0A);017 A 202 (-2.9A);017 A 201 ( 3.5A);017 A 202 (-4.0A)","0.36A","3lzsA-3u7sA:19.8","3lzsA-3u7sA:76.77"],["3LZS_A_017A200_1","3uhl","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;PRO A  81;VAL A  82","None","0.42A","3lzsA-3uhlA:16.4","3lzsA-3uhlA:80.81"],["3LZS_A_017A200_1","4clc","Saccharomyces cerevisiae","UPF0303 PROTEIN YBR137W","PF03928(Haem_degrading)",5,"LEU E 151;ALA E 160;GLY E  43;VAL E  59;ILE E 148","None","0.95A","3lzsA-4clcE:undetectable","3lzsA-4clcE:18.44"],["3LZS_A_017A200_1","4g09","Brucella suis","HISTIDINOL DEHYDROGENASE","PF00815(Histidinol_dh)",6,"LEU A 240;ALA A 243;ASP A 244;GLY A 352;ILE A 351;ILE A 241","None","1.35A","3lzsA-4g09A:undetectable","3lzsA-4g09A:12.33"],["3LZS_A_017A200_1","4gbr","Homo sapiens","BETA-2 ADRENERGIC RECEPTOR","PF00001(7tm_1)",5,"VAL A  44;GLY A  90;ILE A  94;VAL A  39;ILE A  43","None","0.87A","3lzsA-4gbrA:undetectable","3lzsA-4gbrA:12.66"],["3LZS_A_017A200_1","4inj","Listeria monocytogenes","LMO1638 PROTEIN","PF02016(Peptidase_S66)",5,"LEU A 162;ALA A 309;GLY A 306;ILE A 305;ILE A 321","None","0.84A","3lzsA-4injA:undetectable","3lzsA-4injA:16.29"],["3LZS_A_017A200_1","4kpo","Zea mays","NUCLEOSIDE N-RIBOHYDROLASE 3","PF01156(IU_nuc_hydro)",5,"GLY A  10;ASP A  12;GLY A 124;ILE A  34;ILE A  17","None; CA A 401 ( 4.8A); CA A 401 ( 4.3A);None;None","0.89A","3lzsA-4kpoA:undetectable","3lzsA-4kpoA:17.73"],["3LZS_A_017A200_1","4lom","Mycobacterium tuberculosis","IMIDAZOLEGLYCEROL-PHOSPHATE DEHYDRATASE","PF00475(IGPD)",5,"LEU A 165;GLY A  84;ALA A 161;VAL A 116;ILE A 163","None","0.85A","3lzsA-4lomA:undetectable","3lzsA-4lomA:19.44"],["3LZS_A_017A200_1","4m2j","Streptomyces lavendulae","AMINOTRANSFERASE","PF00155(Aminotran_1_2)",5,"GLY A 278;ALA A 281;VAL A 311;GLY A 228;ILE A 200","None","0.93A","3lzsA-4m2jA:undetectable","3lzsA-4m2jA:14.29"],["3LZS_A_017A200_1","4maa","Pseudomonas protegens","PUTATIVE BRANCHED-CHAIN AMINO ACID ABC TRANSPORTER, PERIPLASMIC AMINO ACID-BINDING PROTEIN","PF13458(Peripla_BP_6)",5,"LEU A 105;GLY A 128;ALA A 129;ASP A 130;GLY A 179","GOL A 503 ( 4.4A);GOL A 503 (-3.7A);None;None;None","0.90A","3lzsA-4maaA:undetectable","3lzsA-4maaA:13.15"],["3LZS_A_017A200_1","4na3","Bacillus subtilis","POLYKETIDE SYNTHASE PKSJ","PF00109(ketoacyl-synt);PF02801(Ketoacyl-synt_C);PF16197(KAsynt_C_assoc)",5,"LEU A 180;GLY A 201;ALA A 200;ILE A  12;ILE A 183","None","0.97A","3lzsA-4na3A:undetectable","3lzsA-4na3A:9.92"],["3LZS_A_017A200_1","4njv","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",5,"ALA A  28;ASP A  29;ASP A  30;GLY A  48;ILE A  84","RIT A 500 (-3.6A);RIT A 500 (-3.2A);RIT A 500 (-4.8A);RIT A 500 (-4.8A);RIT A 500 (-4.3A)","0.73A","3lzsA-4njvA:20.1","3lzsA-4njvA:82.83"],["3LZS_A_017A200_1","4njv","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;PRO A  81;ILE A  84","None;RIT A 500 (-2.4A);RIT A 500 (-3.9A);RIT A 500 (-3.6A);RIT A 500 (-3.2A);RIT A 500 (-4.8A);None;RIT A 500 (-3.9A);RIT A 500 (-4.3A)","0.49A","3lzsA-4njvA:20.1","3lzsA-4njvA:82.83"],["3LZS_A_017A200_1","4njv","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None;RIT A 500 (-2.4A);RIT A 500 (-3.9A);RIT A 500 (-3.6A);RIT A 500 (-3.2A);None;RIT A 500 (-3.4A);RIT A 500 (-4.3A);RIT A 500 (-3.9A);RIT A 500 (-4.3A)","0.39A","3lzsA-4njvA:20.1","3lzsA-4njvA:82.83"],["3LZS_A_017A200_1","4qlz","Schistosoma japonicum","SJCHGC07024 PROTEIN","PF00719(Pyrophosphatase)",5,"LEU A  17;GLY A  20;PRO A  31;VAL A  30;ILE A  24","None","0.74A","3lzsA-4qlzA:undetectable","3lzsA-4qlzA:15.19"],["3LZS_A_017A200_1","4r1u","Medicago truncatula","CINNAMOYL COA REDUCTASE","PF01370(Epimerase)",5,"GLY A  97;ASP A  59;GLY A   8;VAL A  70;ILE A  66","None","0.87A","3lzsA-4r1uA:undetectable","3lzsA-4r1uA:14.38"],["3LZS_A_017A200_1","4rwe","Yersinia pestis","SUGAR-BINDING TRANSPORT PROTEIN","PF13407(Peripla_BP_4)",5,"GLY A 196;ALA A 190;ILE A 223;VAL A 214;ILE A 156","None;None;GOL A 401 ( 4.2A);None;None","0.90A","3lzsA-4rweA:undetectable","3lzsA-4rweA:18.91"],["3LZS_A_017A200_1","4rzk","Sulfolobus solfataricus","SMALL HEAT SHOCK PROTEIN HSP20 FAMILY","PF00011(HSP20)",5,"LEU A 121;ALA A  87;ILE A  90;PRO A 139;ILE A 136","None","0.92A","3lzsA-4rzkA:undetectable","3lzsA-4rzkA:25.71"],["3LZS_A_017A200_1","4tnb","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 5","PF00069(Pkinase);PF00615(RGS)",5,"LEU A  45;ASP A  52;GLY A  63;ILE A  62;ILE A  49","None","0.90A","3lzsA-4tnbA:undetectable","3lzsA-4tnbA:10.81"],["3LZS_A_017A200_1","4ydf","Primate T-lymphotropic virus 1","HTLV-1 PROTEASE","PF00077(RVP)",7,"ASP A  32;GLY A  34;ALA A  35;ASP A  36;VAL A  39;GLY A  58;ILE A 100","4B1 A 201 (-2.9A);4B1 A 201 ( 4.6A);4B1 A 201 (-3.6A);4B1 A 201 (-4.4A);None;4B1 A 201 (-3.4A);4B1 A 201 (-4.8A)","0.53A","3lzsA-4ydfA:13.1","3lzsA-4ydfA:32.48"],["3LZS_A_017A200_1","4ydf","Primate T-lymphotropic virus 1","HTLV-1 PROTEASE","PF00077(RVP)",7,"LEU A  30;ASP A  32;GLY A  34;ALA A  35;ASP A  36;GLY A  58;ILE A 100","None;4B1 A 201 (-2.9A);4B1 A 201 ( 4.6A);4B1 A 201 (-3.6A);4B1 A 201 (-4.4A);4B1 A 201 (-3.4A);4B1 A 201 (-4.8A)","0.43A","3lzsA-4ydfA:13.1","3lzsA-4ydfA:32.48"],["3LZS_A_017A200_1","4z26","Acanthamoeba polyphaga mimivirus","PUTATIVE GMC-TYPE OXIDOREDUCTASE R135","PF00732(GMC_oxred_N);PF05199(GMC_oxred_C)",5,"LEU A  36;VAL A 296;ILE A 267;VAL A  10;ILE A  12","None","0.79A","3lzsA-4z26A:undetectable","3lzsA-4z26A:9.17"],["3LZS_A_017A200_1","4ztk","Legionella pneumophila","CELL DIVISION PROTEIN FTSI\/PENICILLIN BINDING PROTEIN 2","PF00905(Transpeptidase)",5,"LEU A 512;ALA A 367;GLY A 364;ILE A 600;ILE A 509","None","0.97A","3lzsA-4ztkA:undetectable","3lzsA-4ztkA:16.61"],["3LZS_A_017A200_1","5b18","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",6,"GLY A  27;ALA A  28;ASP A  29;ASP A  30;PRO A  81;ILE A  84","None","0.40A","3lzsA-5b18A:17.7","3lzsA-5b18A:72.73"],["3LZS_A_017A200_1","5b18","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",5,"GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  84","None","0.73A","3lzsA-5b18A:17.7","3lzsA-5b18A:72.73"],["3LZS_A_017A200_1","5cw5","Camponotus floridanus","BRCA1\/BRCA2-CONTAINING COMPLEX SUBUNIT 3","PF01398(JAB)",5,"LEU A  79;VAL A  89;GLY A  33;ILE A  51;ILE A  36","None","0.96A","3lzsA-5cw5A:undetectable","3lzsA-5cw5A:14.90"],["3LZS_A_017A200_1","5fmg","Plasmodium falciparum","PROTEASOME, PUTATIVE","PF00227(Proteasome)",5,"ASP H 157;VAL H  12;ILE H  37;VAL H 231;ILE H 233","None","0.95A","3lzsA-5fmgH:undetectable","3lzsA-5fmgH:14.40"],["3LZS_A_017A200_1","5h1k","Homo sapiens","GEM-ASSOCIATED PROTEIN 5","PF00400(WD40);PF12894(ANAPC4_WD40)",5,"LEU A 157;GLY A 132;VAL A 177;VAL A 167;ILE A 169","None","0.76A","3lzsA-5h1kA:undetectable","3lzsA-5h1kA:9.04"],["3LZS_A_017A200_1","5h34","Nanoarchaeum equitans","METHIONINE-TRNA LIGASE","PF01588(tRNA_bind)",5,"LEU A 713;GLY A 716;VAL A 690;VAL A 704;ILE A 702","None","0.94A","3lzsA-5h34A:undetectable","3lzsA-5h34A:17.81"],["3LZS_A_017A200_1","5h4b","Mus musculus","CEREBELLIN-4","PF00386(C1q)",5,"GLY A 143;ALA A 142;VAL A 117;GLY A 173;VAL A 120","None","0.98A","3lzsA-5h4bA:undetectable","3lzsA-5h4bA:19.02"],["3LZS_A_017A200_1","5hs0","synthetic construct","ANKYRIN DOMAIN PROTEIN ANK1C4_7","PF12796(Ank_2)",5,"LEU A 121;GLY A 126;ALA A 127;ASP A 128;VAL A  86","None","0.96A","3lzsA-5hs0A:undetectable","3lzsA-5hs0A:19.33"],["3LZS_A_017A200_1","5t2z","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;GLY A  49;PRO A  81","None","1.39A","3lzsA-5t2zA:21.0","3lzsA-5t2zA:77.78"],["3LZS_A_017A200_1","5t2z","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.26A","3lzsA-5t2zA:21.0","3lzsA-5t2zA:77.78"],["3LZS_A_017A200_1","5u2w","Burkholderia cenocepacia","SHORT CHAIN DEHYDROGENASE","PF00106(adh_short)",5,"ALA A 170;ASP A 172;GLY A 164;ILE A 163;VAL A 137","None","0.95A","3lzsA-5u2wA:undetectable","3lzsA-5u2wA:17.58"],["3LZS_A_017A200_1","5ve3","Paraburkholderia phytofirmans","BPPRF","no annotation",5,"GLY B  88;ALA B  89;ASP B  90;VAL B  59;ILE B  80","None","0.72A","3lzsA-5ve3B:undetectable","3lzsA-5ve3B:14.00"],["3LZS_A_017A200_1","5vm2","Escherichia coli","ALCOHOL DEHYDROGENASE","PF00107(ADH_zinc_N);PF08240(ADH_N)",5,"GLY A 237;ALA A 238;ASP A 239;VAL A 199;ILE A 173","None","0.83A","3lzsA-5vm2A:undetectable","3lzsA-5vm2A:15.68"],["3LZS_A_017A200_1","5xj1","Streptococcus pneumoniae","UNCHARACTERIZED RNA METHYLTRANSFERASE SP_1029","no annotation",5,"GLY A 399;ALA A 400;ASP A 401;ILE A 373;ILE A 378","None","0.89A","3lzsA-5xj1A:undetectable","3lzsA-5xj1A:14.96"],["3LZS_A_017A200_1","6b92","Homo sapiens","U6 SMALL NUCLEAR RNA (ADENINE-(43)-N(6))-METHYLTRANSFERASE","no annotation",5,"GLY A 121;ALA A 122;GLY A 106;VAL A 157;ILE A 155","None","0.95A","3lzsA-6b92A:undetectable","3lzsA-6b92A:15.69"],["3LZS_A_017A200_1","6fiv","Feline immunodeficiency virus","RETROPEPSIN","PF00077(RVP)",6,"LEU A  28;ASP A  30;GLY A  32;ALA A  33;ASP A  34;GLY A  58","None;3TL A 201 (-3.5A);3TL A 201 (-3.4A);3TL A 201 (-4.0A);3TL A 201 (-3.9A);3TL A 201 (-3.4A)","0.19A","3lzsA-6fivA:15.5","3lzsA-6fivA:29.57"],["3LZS_A_017A200_1","6fiv","Feline immunodeficiency virus","RETROPEPSIN","PF00077(RVP)",6,"LEU A  28;ASP A  30;GLY A  32;ALA A  33;ASP A  34;VAL A  99","None;3TL A 201 (-3.5A);3TL A 201 (-3.4A);3TL A 201 (-4.0A);3TL A 201 (-3.9A);None","0.45A","3lzsA-6fivA:15.5","3lzsA-6fivA:29.57"],["3LZS_A_017A200_1","6upj","Human immunodeficiency virus 2","HIV-2 PROTEASE","PF00077(RVP)",8,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;ASP A  30;GLY A  49;PRO A  81;ILE A  84","None;NIU A 100 (-2.8A);NIU A 100 (-3.6A);None;None;NIU A 100 ( 3.8A);None;None","0.63A","3lzsA-6upjA:18.2","3lzsA-6upjA:51.52"],["3LZS_A_017A200_1","6upj","Human immunodeficiency virus 2","HIV-2 PROTEASE","PF00077(RVP)",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  84","None;NIU A 100 (-2.8A);NIU A 100 (-4.5A);NIU A 100 (-3.6A);None;None;NIU A 100 ( 3.8A);None","0.60A","3lzsA-6upjA:18.2","3lzsA-6upjA:51.52"],["3LZS_A_017A200_1","6upj","Human immunodeficiency virus 2","HIV-2 PROTEASE","PF00077(RVP)",7,"LEU A  23;ASP A  29;ASP A  30;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None;None;None;NIU A 100 ( 3.8A);NIU A 100 (-3.9A);None;None","0.85A","3lzsA-6upjA:18.2","3lzsA-6upjA:51.52"],["3LZS_A_017A200_1","6upj","Human immunodeficiency virus 2","HIV-2 PROTEASE","PF00077(RVP)",6,"LEU A  23;ASP A  30;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None;None;NIU A 100 ( 3.8A);NIU A 100 (-3.9A);None;None","1.22A","3lzsA-6upjA:18.2","3lzsA-6upjA:51.52"],["3LZS_A_017A200_1","6upj","Human immunodeficiency virus 2","HIV-2 PROTEASE","PF00077(RVP)",7,"LEU A  23;GLY A  27;ASP A  29;ASP A  30;GLY A  49;ILE A  50;ILE A  84","None;NIU A 100 (-4.5A);None;None;NIU A 100 ( 3.8A);NIU A 100 (-3.9A);None","0.78A","3lzsA-6upjA:18.2","3lzsA-6upjA:51.52"]]